Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
I-131-labelled anti-neurophysin antibody is an investigational radiopharmaceutical consisting of rabbit polyclonal antibodies conjugated with the radioisotope Iodine-131. It specifically targets vasopressin-associated human neurophysin (VP-HNP), a carrier protein that is ectopically produced and expressed on the surface of approximately 65-70% of small cell lung carcinoma (SCLC) cells. The agent was designed to bind to these tumor-associated antigens, thereby delivering targeted radiation for tumor localization and imaging via scintigraphy. Preliminary clinical studies conducted in the late 1980s demonstrated successful tumor imaging in patients with neurophysin-producing SCLC. However, the development of this specific agent did not progress beyond early clinical trials to regulatory approval.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on I-131-labelled anti-neurophysin antibody.